This is not the most recent version of the article. View current version (5 NOV 2013)

Intervention Review

Pimozide for schizophrenia or related psychoses

  1. John Rathbone1,*,
  2. Tom McMonagle2

Editorial Group: Cochrane Schizophrenia Group

Published Online: 18 JUL 2007

Assessed as up-to-date: 16 MAY 2007

DOI: 10.1002/14651858.CD001949.pub2


How to Cite

Rathbone J, McMonagle T. Pimozide for schizophrenia or related psychoses. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD001949. DOI: 10.1002/14651858.CD001949.pub2.

Author Information

  1. 1

    The University of Sheffield, HEDS, ScHARR, Sheffield, UK

  2. 2

    St. Vincent's University Hospital, c/o St Camillus's Ward, Dublin 4, Ireland

*John Rathbone, HEDS, ScHARR, The University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, UK. J.Rathbone@sheffield.ac.uk. John.Rathbone@nottingham.ac.uk.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 18 JUL 2007

SEARCH

This is not the most recent version of the article. View current version (05 NOV 2013)

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Stefan Leucht, Jürgen Fritze, Mario Horst Lanczik, Roland Vauth, Hans Michael Olbrich, Psychische Erkrankungen, 2012,

    CrossRef

  2. 2
    Magdolna Tardy, Stefan Leucht, Andrey Potapov, Rolf Engel, Maximilian Huhn, Werner Kissling, Fluphenazine versus low-potency first generation antipsychotic drugs for schizophrenia, The Cochrane Library,
  3. 3
    Meghana Mothi, Stephanie Sampson, Pimozide for schizophrenia or related psychoses, The Cochrane Library,
  4. 4
    Magdolna Tardy, Stefan Leucht, Andrey Potapov, Rolf Engel, Markus Dold, Werner Kissling, Trifluoperazine versus low-potency first generation antipsychotic drugs for schizophrenia, The Cochrane Library,
  5. 5
    Magdolna Tardy, Markus Dold, Rolf R Engel, Stefan Leucht, Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophrenia, The Cochrane Library,